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Abstract
Skeletal muscle is a large organ that accounts for up to half the total mass of the human body. A progressive decline in muscle
mass and strength occurs with ageing and in some individuals configures the syndrome of ‘sarcopenia’, a condition that
impairs mobility, challenges autonomy, and is a risk factor for mortality. The mechanisms leading to sarcopenia as well as
myopathies are still little understood. The Human Skeletal Muscle Proteome Project was initiated with the aim to characterize
muscle proteins and how they change with ageing and disease. We conducted an extensive review of the literature and
analysed publically available protein databases. A systematic search of peer-reviewed studies was performed using PubMed.
Search terms included ‘human’, ‘skeletal muscle’, ‘proteome’, ‘proteomic(s)’, and ‘mass spectrometry’, ‘liquid chromatography-
mass spectrometry (LC-MS/MS)’. A catalogue of 5431 non-redundant muscle proteins identified by mass spectrometry-based
proteomics from 38 peer-reviewed scientific publications from 2002 to November 2015 was created. We also developed a
nosology system for the classification of muscle proteins based on localization and function. Such inventory of proteins should
serve as a useful background reference for future research on changes in muscle proteome assessed by quantitative mass
spectrometry-based proteomic approaches that occur with ageing and diseases. This classification and compilation of the
human skeletal muscle proteome can be used for the identification and quantification of proteins in skeletal muscle to discover
new mechanisms for sarcopenia and specific muscle diseases that can be targeted for the prevention and treatment.
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Introduction
Skeletal muscle is one of the most abundant tissues in
mammals, accounting for up to 40% of the total mass of
the human body.1 The human skeletal muscle is a complex
organ made up of multinucleated long and cylindrical cells
called myofibres that are, in turn, composed of myofibrils.
Myofibrils consist of proteins called myofilaments, mainly
actins and myosins, that form the sarcomeres, which are
the smallest contractile units. The contraction–relaxation
cycle in muscle requires energy that is mostly generated
aerobically by mitochondria particularly abundant in adult
muscle fibres. Contraction is stimulated by motor neurons
that are resident in the spinal cord and connect with
muscle fibres through a specialized synapsis known as the
neuromuscular junction. Acetylcholine released into the
neuromuscular junction cleft interacts with specific recep-
tors and generates an action potential across the surface
of the muscle cell that rapidly diffuses within the muscle
fibres through a network of specialized tubules called T
tubules. The action potential triggers the opening of the
dihydropyridine receptor that allows influx of calcium (Ca2+)
in the cytoplasm that stimulates ryanodine receptors to
release more Ca2+ from the sarcoplasmic reticulum. Ca2+, in
turn, triggers the interaction between contractile proteins
and elicits a shortening of the muscle fibre.2 Such structural
and functional complexity is mirrored by the large repertoire
of proteins found in skeletal muscle.
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Maintenance of muscle mass and effective muscle function
throughout life is essential to preserve a healthy and active
lifespan and to maintain physical function and autonomy in
old age. Conversely, the development of overt sarcopenia
has devastating consequences on individuals’ life because it
is associated with mobility loss, higher risk of disability,
nursing home admission, and death.3,4 Thus, understanding
the causal pathways leading to age-related sarcopenia and
develop strategies for prevention and cure of this condition
is essential to improve the well-being and quality of life of a
growing number of older individuals in the population. There
is strong evidence that diabetes type 2, cancer, chronic kidney
diseases, chronic pulmonary disease, and bed rest cause ac-
celerated muscle mass and strength, which is superimposed
to the effect of ageing. However, the mechanisms by which
ageing and diseases cause sarcopenia are still not fully
understood and may be quite different. With the exception
of exercise, there is currently no effective treatment for
sarcopenia.
Most of current research on sarcopenia is based on clinical
characterization, analysis of blood biomarkers, and examina-
tion of muscle biopsies.5–8 Histological examination of muscle
specimens is generally considered as the gold standard
test for most myopathies but, especially for age-related
sarcopenia, histology lacks diagnostic specificity and has
limited value for monitoring the effect of interventions.
We propose that proteomic analysis of muscle tissue,
especially using a discovery approach complemented by
targeted, quantitative mass spectrometry (MS), may over-
come the many limitations of previous approaches to the
study of sarcopenia. Specific proteomic signatures, or the
overrepresentation or underrepresentation of certain pro-
teins or even the altered stoichiometric interrelationship
between proteins, may provide clues on the processes that
lead to muscle impairments, perhaps also allowing the diag-
nosis of the different conditions, including age-related
sarcopenia. For example, changes in mitochondrial proteins
may suggest that scarcity of energy is at the root of muscle
degeneration. Also, proteomics could be used to monitor at
an early stage the potential effectiveness of intervention
aimed at normalizing muscle. This approach would add con-
siderable value to the simple monitoring muscle mass and
strength. In fact, interventions aimed at expanding muscle
mass, such a testosterone or selective androgen receptor
modulators, have shown little impact on physical functions
such as walking performance; the structural and biochemical
reasons for such a discrepancy are not clear.9,10 On the
other hands, modifications in abundance of specific muscle
proteins may occur long before any improvement in strength
is clinically detectable. Overall, the complementary use of
advanced high-sensitivity discovery-mode and targeted,
quantitative MS/MS proteomic analysis of skeletal muscle
specimens may provide new insights into the pathogenesis
of skeletal muscle in health and disease through the
characterization of protein abundance, quality, and diversity,
including their isoforms and post-translational modifications
(PTMs). Application of proteomics may help to identify bio-
markers of adaptive or maladaptive biological mechanisms
manifested during ageing or diseases.
A critical step for making progress in this field is a
comprehensive characterization and classification of the
human skeletal proteome. Because it is well known that
muscles are different in men and women and change
substantially with ageing, such normative data will have to
be developed in men and women of different age, possibly
free of major conditions or treatment that may affect
muscle proteins. Similarly, it is important to have an avail-
able annotation system that characterize proteins in terms
of their cell localization and function.
We performed a search of the literature of published
studies that had reported on skeletal muscle proteomic
analyses in humans. The goal of this review is to summarize
the state of the art in muscle proteomic research as the first
step of a new initiative of the Biology/Disease-driven Human
Proteome Project.11 Then, using data from available data-
bases and an extensive review of the literature, we created
a refined annotation system that improved our ability to
classify muscle proteins based on their cellular localization
and function. Finally, we outline what research should be
performed to create a reference atlas of the normal, human
skeletal muscle proteome.
Human skeletal muscle proteome
Caveats and challenges in performing and
interpreting skeletal muscle proteomics
Human skeletal muscle has mainly been studied in muscle
biopsies obtained under local anaesthesia. The percutaneous
needle introduced by Bergstrom in 196212 yields useful
biopsy material (around 100–300mg) that has been used
successfully for proteomic analysis conducted by MS.13
Previous attempts to characterize the muscle proteomics
have been incomplete14 and mostly focused on muscular
dystrophies.15,16 Although there are hundreds of skeletal
muscles in the body, nearly all proteomic studies have
focused on vastus lateralis, quadriceps, and deltoid muscles,
and therefore, most of the current knowledge is skewed
towards these muscles. This is problematic because different
muscles may have quite distinct protein composition affected
by different content in adipose and connective tissue, degree
of vascularization and innervation, and fibre type composi-
tion. Skeletal muscle fibres can be divided mainly into three
main subtypes distinguished by their contractile and meta-
bolic properties: (A) slow, oxidative, type 1 fibres (measured
by staining myosin-7, encoded by MYH7); (B) fast, oxidative,
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type 2A fibres (measured by myosin 2, encoded by MYH2);
(C) fast, glycolytic, type 2x fibres (measured by myosin-1,
encoded by MYH1).17 The relative percentage of fibre types
tends to be muscle specific and is also affected by the overall
level of physical activity and metabolic diseases such as
diabetes.18–20 All these factors may affect protein synthesis
and degradation. The large number of proteins and the wide
dynamic range in abundance of different proteins in skeletal
muscle are one of main challenges in performing high-fidelity
proteomics. In fact some of the largest (titin) and smallest
(phospholamban) proteins in the human proteome are found
in this tissue. In addition, sample preparation becomes
critically important because the contractile proteins are so
abundant that without adequate fractionation, the chance
to detect low abundant proteins, such as signalling enzymes,
becomes low.
Conditions and factors affecting the composition of
the human skeletal muscle proteome
Skeletal muscle not only contains proteins that pertain to
muscle cells but also is unavoidably contaminated by proteins
that pertain to adipose, connective, vascular, and neural
tissue. To better understand the difference between speci-
mens, proteins should be classified based on the subcellular
localization (i.e. contractile apparatus, nuclei, mitochondria,
sarcoplasmic reticulum, transverse tubules, Golgi apparatus,
sarcolemma, extracellular matrix, ribosomes, cytoskeleton,
and the cytosolic fraction)21 function and metabolic and sig-
nalling pathways (i.e. glucose metabolism, electron transport
chain and OXPHOS system, and calcium homeostasis).22–25
Early proteomic studies identified that most of the proteins
of skeletal muscle are localized in the sarcomere (i.e. myo-
sins, actins, troponins, tropomyosins, and auxiliary proteins
of sarcomeric units), representing about 55–60% of the total
proteins.18,22,26–28 Mitochondrial proteins constitute around
28% of the transcripts found in skeletal muscle confirming
the importance muscle in the energy metabolism.29 Of note,
most of these proteins, especially sarcomeric, glycolytic, and
mitochondrial proteins exist in different isoforms (i.e. myosin
has more than 20 isoforms), therefore highly affecting the
functionality, the integrity, and the protein synthesis in skele-
tal muscle, especially during ageing and some other patho-
logical conditions.
During physical activity or movement, skeletal muscle is
highly metabolically demanding, therefore, a very large num-
ber of proteins and enzymes related with all the metabolic
pathways as well as proteins involved in the cellular stress
response such as heat shock proteins (HSPs) will be prone
to change in abundance during these states.18,30
Also limited literature suggests that contractile, structural,
and mitochondrial proteins, together with metabolic en-
zymes, can all be affected by conditions that affect muscle
health (i.e. diabetes type 2, obesity, ageing, age-related dis-
eases, myopathies, and dystrophies) and behavioural stress
such as extreme exercise.31 Factors in liquid chromatogra-
phy-mass spectrometry (LC-MS/MS) proteomic studies that
have been found to affect muscle proteome composition are
summarized in the next sections and in Table 1.
Ageing
Age-related changes in the contractile apparatus are mainly
the result of transition from fast-twitching fibres (mainly IIx)
to slow-twitching muscle fibres.32–34 Proteomic studies have
been shown that myofibrillar and cytoskeletal proteins are
less abundant in vastus lateralis in older compared with
middle-aged women.27,35 Ageing also appeared to change
the abundance of enzymes involved in oxidative metabolism,
anaerobic metabolism, and the glycolysis pathway, such as
adenosine triphosphate (ATP) syntase β-chain, Acyl-CoA
dehydrogenase, aconitase, 2-oxoglutarate dehydrogenase,
malate dehydrogenase, creatine kinase, glycogen phosphory-
lase, glyceraldehyde-3-phosphate dehydrogenase, among
others.33 Other proteins that are similar to the HSP are
involved in detoxification and cytoprotection functions (i.e.
carbonic anhydrase 3 or elongation factor 2, and ubiquitin-
40S ribosomal protein S27a) decrease during ageing, with
reduced scavenging of reactive oxygen species accumulation
of aggregated proteins.30,35,36
Exercise and physical inactivity
Although it is well known that skeletal muscle adaptations to
exercise depend on duration, intensity, and frequency,37
changes in muscle proteins associated with different types
of exercise have not been well characterized. Myofibrillar
protein isoforms are most affected, mainly in the distribution
of myosin heavy chain isoforms, thin filament isoforms, sar-
coplasmic reticulum calcium proteins, mitochondrial proteins,
and some chaperones involved in cell stress response. Studies
also found (i) changes in fibre type composition; (i) change in
enzymes implicated in energetic metabolism, such as the E3
subunit of the pyruvate dehydrogenase complex, fumarate
hydratase, malate dehydrogenase, and aspartate aminotrans-
ferase; and (iii) expression of some of the components of the
electron transport chain such as complex I, IV, and ATP
synthase subunits, although there is wide heterogeneity
between studies on specific results.38–41
Long bed rest is known to induce considerable atrophy in
lower limb muscles accompanied by a reduction in cross-
sectional area and fascicle length.42 Bed rest proteomic
studies with or without exercise have shown muscle fibre
atrophy accompanied by a deregulation in myosin heavy
chain distribution, downregulation of thin filament proteins,
and changes in fibre type composition (increased type I and
decreased type IIA fibres) in both, vastus lateralis and soleus
muscles. Moreover, these changes are usually accompanied by
(i) down-regulation of proteins involved in aerobic metabolism
The human skeletal muscle proteome project 7
Journal of Cachexia, Sarcopenia and Muscle 2017; 8: 5–18
DOI: 10.1002/jcsm.12121
(i.e. dihydrolipoil dehydrogenase, succinyl-CoA ligase, and
aconitate hydratase between others); (ii) up-regulation of pro-
teins involved in anaerobic glycolysis such as some isoforms of
glycogen phosphorylase and α-enolase; and (iii) down-
regulation of the antioxidant defence system proteins.43,44
Hypoxia and extreme environmental stress
The effects of hypoxia in skeletal muscle remain controversial.
Early reports suggested that chronic hypoxia might positively
affect muscle oxidative capacity and capillarization through
up-regulation of hypoxia inducible factor-1 alpha, the primary
Table 1 Changes in skeletal muscle protein composition caused by aging, age-related diseases and skeletal muscle disease. Black arrow:
downregulation; Red arrow: upregulation
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transcriptional response factor for hypoxic adaptation.45,46
However, continued exposure to hypoxia has negative effects
on muscle structure, producing muscle atrophy.47–49 Using a
proteomic approach, it was found that under hypoxic condi-
tions, vastus lateralis contractile proteins such as the γ-actin
isoform were decreased together with other contractile pro-
teins such as D repeat protein 1, vinculin, tubulin, Kelch repeat,
and desmin. Furthermore, proteins involved in tissue injury
hypoxia (mainly α-enolase), in oxidative metabolism (i.e. 2-
oxoglutarate dehydrogenase, malate dehydrogenase, aconitate
hydratase, and electron transport chain mitochondrial pro-
teins), in fatty acid β oxidation, creatine biosynthesis, lipid per-
oxidation, and proteins involved in oxidative stress protection
were also less abundant under hypoxic conditions.50 A proteo-
mic study that aimed to elucidate the mechanisms by which
Tibetans born and living at high altitude could adapt to hypoxia
found that the most differentially overexpressed proteins in
vastus lateralis compared with subjects living a low altitude
were those related with oxidative and glycolytic pathways such
as glutathione-S-transferase P1-1, Δ2-enoyl-CoA-hydratase,
Nicotinamide adenine dinucleotide (NADH)-ubiquinone oxido-
reductase, myoglobin, glyceraldehyde-3-phosphate dehydro-
genase, and lactate dehydrogenase, suggesting a metabolic
switch to cope with this hypoxic conditions and reinforcing
protection against reactive oxygen species tissue damage.51
Conversely, changes in diet and environment, such as cold
or hot conditions, can negatively impact muscle physiol-
ogy.52,53 The increase of energy expenditure upon cold expo-
sure or dietary changes is called adaptive thermogenesis.54
The exact mechanisms by which skeletal muscle adapts to
thermogenesis still remains unknown and may be related to
changes in the mitochondrial uncoupling.55 A study evaluat-
ing the differences of the human skeletal muscle proteome
under cold and overfeeding conditions found that extreme
conditions produced higher levels of contractile proteins
(including fast and slow isoforms) and metabolic enzymes,
mainly related with glycolysis and fatty acid metabolism,
suggesting that all these modifications were related to alter-
ations in energy expenditure after cold exposure.56
Metabolic diseases and other pathological conditions
Obesity
Accumulation of adipose tissue that occurs with ageing and
the metabolic syndrome, especially ectopic lipid deposition
such as enlarged visceral fat depots, the liver, skeletal muscle,
and other non-adipose tissues, tends to be associated with
loss of muscle mass as well as decline in muscle quality. Obe-
sity may negatively impact human skeletal muscle through
accumulation of lipids such as long-chain diacyl-glycerols or
ceramides, production of inflammatory mediators, interfer-
ence with maintenance, and repair mechanisms and other
still unknown mechanisms.57 Studies conducted on digitonin
extracted cytosolic proteins in rectus abdominal muscle from
obese women have shown increased expression of metabolic
pathway proteins such as adenylate kinase 1, glyceraldehyde-
3-phosphate dehydrogenase, aldolase A, fatty acid-binding
protein 3, and pyruvate kinase, and a decrease in carbonic
anhydrase 3 compared with lean control subjects, suggesting
that these differences represent a compensatory mechanism
to counteract the muscle mitochondrial dysfunction associ-
ated with obesity already described in other studies23,58
Type 2 diabetes
There is strong evidence from epidemiological studies that
people with insulin resistance or type 2 diabetes experience
accelerated decline of muscle strength and muscle mass, al-
though the reason for this association is not clear.59 Defects
in the activity of the metabolic enzymes and in the insulin sig-
nalling pathways associated with decreased muscle glycogen
synthesis have been described in the muscle of these pa-
tients.60,61 Proteomic studies of human skeletal muscle have
shown that proteins involved in the tricarboxylic acid cycle
(TCA cycle), mitochondrial respiration, and other mitochon-
drial functions such as ATP synthase β and α isoform and cre-
atine kinase brain isoform, among others, were less abundant
in vastus lateralis from insulin-resistant subjects, suggesting
an increased glycolytic and decreased mitochondrial protein
abundance together with a shift in muscle properties towards
a fast-twitch pattern in the absence of marked changes in
fibre-type distribution.58,62 Proteins involved in cytoskeletal
structure and function like the actin capping and Z-disc com-
ponent and the four isoforms of α-1 chain of type VI collagen,
isoenzymes of myosin regulatory light chain 2A and B, myosin
15, and troponin isoforms were significantly altered together
with some chaperone and co-chaperone proteins.62,63
Exercise is beneficial in patients with type 2 diabetes and
plays a major role in the prevention and control of insulin
resistance.64 Proteomic studies have shown that a 4 week
training programme of endurance exercise in patients with
type 2 diabetes increased proteins in vastus lateralis involved
in energy metabolism via glycolysis, TCA cycle, electron trans-
port chain, and β-oxidation, mainly lactate dehydrogenase
B chain, mitochondrial creatine kinase, aspartate aminotrans-
ferase acetyl-coA-acetyltransferase, cytochrome b-c1 complex
subunit 2, isoform 1 of succinyl-CoA ligase (ADP-forming)
subunit beta, isoform cytoplasmic of fumarate hydratase,
and isocitrate dehydrogenase. There was also a reduction
in the levels of glycolytic proteins, including isoform 1 of
6-phosphofructokinase, fructose-biophosphate aldolase A,
and lactoylglutathione lyase, or glyoxalase 1.65
Speciﬁc muscle diseases and neuromuscular disorders
Proteomic studies performed in skeletal muscle from patients
with skeletal muscle diseases such as hereditary inclusion
body myopathy, myofibrillar myopathies, desminopathies,
and some muscle disorders caused by collagen VI mutations
have shown that the most abundant changes are found in
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proteins related to cytoskeleton and sarcomere functions,
basically caused by mutations in genes encoding sarcomeric
and extra-sarcomeric proteins.66–70 This will affect not only
the skeletal muscle but also their connectives tissues produc-
ing contractures and muscle weakness.
Similar results have been found in patients with amyotro-
phic lateral sclerosis a severe and fatal neurodegenerative
disease characterized by the selective death of motor neu-
rons in the motor cortex, brainstem, and spinal cord.71,72
The pathogenesis of this disease is still unknown, but it has
been suggested that skeletal muscle could play an important
pathogenic role.71,73
Post-translational modiﬁcations in skeletal muscle
proteome
Post-translational modifications are chemical alterations to
protein structure, typically catalysed by substrate-specific
enzymes that may change the properties of a protein by
proteolytic cleavage or by addition of a modifying group to
one or more amino acids.74 More than 300 different types
of PTMs are known, and many are implicated in diseases such
as cancer, ageing, and age-related diseases.75,76 Protein
phosphorylation and acetylation play key roles in signal trans-
duction pathways regulating energy metabolism, contractile
function, and muscle mass in human skeletal muscle, but
the role of protein phosphorylation and acetylation in normal
skeletal muscle and in skeletal muscle disorders remains still
poorly understood because of technical limitations related to
both the stability of PTMs in collected biopsies and limits of
proteomic technology (see succeeding text).
In the first global analysis of the in vivo
phosphoproteome of human skeletal muscle from vastus
lateralis in healthy subjects, 367 phosphorylation sites
in 144 phosphoproteins/phosphoprotein groups were
described. More than one-quarter were sarcomeric proteins
from the contractile apparatus, such as thin actin and thick
myosin-containing filaments, and M-line and Z-disc-
associated proteins. Other phosphorylation sites were iden-
tified in some enzymes of glycogen metabolism and in
some kinase and phosphates subunits that regulate the
phosphorylation of glycogen synthase and phosphory-
lase.22,77 In mitochondria isolated from vastus lateralis,
other authors identified 155 distinct phosphorylation sites
in 77 mitochondrial phosphoproteins mainly involved in ap-
optosis, oxidative phosphorylation (the most abundant),
TCA cycle, fatty transporters and β-oxidation, amino acid
degradation, import machinery and transporters, and
calcium homeostasis. The authors suggested that reversible
phosphorylation of mitochondrial proteins may play a role
in the mitochondrial dysfunction that is found in different
pathologies such as muscle disorders, type 2 diabetes, and
age-related diseases.78
In another study, the same investigators examined the
effects of 4 h stimulation with physiological levels of insulin
on the phosphorylation of mitochondrial proteins in human
skeletal muscle in vivo in healthy individuals.79 They identi-
fied 207 phosphorylation sites, of which 45% were identified
both in basal and insulin-stimulated samples, whereas almost
half of them were identified exclusively in the insulin-
stimulated samples. The most abundant phosphoproteins
were those involved in oxidative phosphorylation and the
TCA cycle. Furthermore, they found multiple phosphorylation
sites in components of the mitochondrial inner membrane
organizing system. The authors concluded that these results
suggest that insulin might regulate the phosphorylation of
mitochondrial proteins in skeletal muscle. Also, a recent
phosphoproteomic study in human skeletal muscle showed
that some 5’ adenosine monophosphate activated protein
kinase (AMPK) substrates regulate mitochondrial respiration
in response to exercise via phosphorylation.80
Finally, another proteomic study comparing skeletal mus-
cle from obese with or without type 2 diabetes found signif-
icant differences in phosphorylation and ubiquitinylations in
some of the most important glycolytic enzymes such as glyco-
gen phosphorylase muscle isoform, β-enolase, and pyruvate
kinase 2 together with other contractile and cytoskeleton
proteins such as glyceraldehyde 3-phosphate dehydrogenase,
myosin regulatory light chain 2, ventricular/cardiac muscle,
and myosin regulatory light chain 2 skeletal muscle.81
Compilation of the current human
skeletal muscle proteome
In order to compile a comprehensive atlas of the skeletal
muscle proteome, we searched PubMed using the terms
‘skeletal muscle’ combined with either ‘proteome’, ‘proteo-
mics’, ‘MS’, and ‘LC-MS/MS’, using a filter for ‘human’ and
published before December 2015. Papers were excluded if
they involved proteomic investigations of human cell lines
or studies in which low abundance of proteins were detected
using immunological methods rather than proteomic and MS
approaches. Thirty-eight publications fit the aforementioned
criteria and were used for compiling the human skeletal
muscle proteome (Figure 1). The Uniprot database was used
as the authoritative reference for human proteins. Lists of
proteins were compiled for each paper based upon protein
data in the published tables and/or supplementary tables.
In order to combine all protein identifications into one list,
International protein index accessions and National Center
for Biological Information protein accessions were converted
to Uniprot accessions by Uniprot ID conversion.82 Several
classes of proteins were removed from the resulting set.
Proteins that have been merged into other accession
numbers or removed from their respective databases were
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considered obsolete and removed. Proteins that were
duplicated between identifications were also reduced to the
single identification. Finally, obvious contaminants, which
were decoy proteins, trypsin, and non-human proteins, were
removed. The final filtered list that contained 5431 proteins
were identified for the human skeletal muscle proteome.
We also identified the top 20 most reported skeletal muscle
proteins from the 38 publications (Figure 2).
The neXtProt database is a recently developed database,
which incorporates only high-quality, well-studied proteins
as the human proteome.83 Therefore, we used this neXtProt
to validate our final human skeletal muscle proteome. In
our list of 5431, 4947 had neXtProt accessions (Table S1).
There were 484 proteins without neXtProt accessions
(Table S1, sheet 2) as of December 2015. The high rate of
concordance between neXtProt and our dataset shows that
Figure 2 Top 20 proteins in human skeletal muscle proteome. Most reported skeletal muscle proteome from all 38 publications.
Figure 1 Mass spectrometry-based human skeletal muscle publications and proteins. We compiled mass spectrometry-based human skeletal
muscle proteome papers since 2003. The X axis contains the ﬁrst author, year of publication, and how many new proteins were discovered in
skeletal muscle in the study. Colour-coded circles show what mass spectrometer was primarily used by each study. The Y axis shows the total
number of proteins identiﬁed by each study.
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we have a proper filtering method that provided a quite
comprehensive collection of the proteome.
Many of the earlier studies of the human skeletal muscle
proteome involved two-dimensional gel electrophoresis
and Matrix-assisted laser desorption/ionization- time of flight
(MALDI-TOF), a workflow that is mainly useful to
identify proteins that are differentially expressed between
groups.25,33,36,51,58,62 In compiling this list of human skeletal
muscle proteins from that manuscripts, we encountered
several problems: (i) papers based on earlier technology
may have been limited by ambiguous identification of pro-
teins; (ii) most studies did not state the precise criteria used
to identify proteins, including false discovery rates (FDR) for
peptides and proteins; (iii) some reported isoforms have no
accompanying peptide data, thus, it is not possible to deter-
mine whether a peptide amino acid sequence that is unique
to the specific isoform was actually observed; (iv) most
studies did not provide spectra and did not have raw MS data
available in a public repository for further inspection and
corroboration; and (v) a few studies did not even specify
which skeletal muscle was biopsied for study. Some studies
used an FDR for proteins >1%, which by current standards
is not considered to be sufficiently rigorous. For example,
the Plasma Peptide Atlas uses a stringent 1% FDR for proteins
(which corresponds to a 0.2% FDR at the peptide level). If
such stringent criteria were applied to the human skeletal
muscle proteome, as compiled in the present paper, the
number of identifications would be anticipated to be less
than 5431 non-redundant proteins in Table S1. However, in
certain cases, an investigator may be justified in allowing an
FDR up to 5%, in particular for older mass spectrometers. Fur-
thermore, we also note that the question of the correct
method of calculating FDR is not completely settled.84,85
Therefore, for our list, we accept identifications reported at
the thresholds from published datasets. In the future, the
redundancy of protein identifications and quality of reporting
of peptide data from the human skeletal muscle could be
improved with standards established by the human skeletal
muscle proteome initiative.
Finally, we compared our proteome to three other
datasets relevant to the skeletal muscle proteome: a non-
MS, antibody-based, global human proteome, called Human
Protein Atlas28,86,87; a mouse proteomics dataset from
skeletal muscle88,89; and an RNA-seq dataset produced from
human skeletal muscle from 361 individuals, from the
Genotype-tissue Expression (GTEx) project.90 While we are
interested in the MS-based human proteome, transcript data
and antibody-based protein data can still inform the analysis
of proteomics data, and mouse skeletal muscle is also a
useful comparison. In order to translate between transcript
and protein, and between mouse and human, we compared
all three skeletal muscle studies at the genome level. In
mouse skeletal muscle, there were 9887 genes reported
from 10 218 proteins, while Human Protein Atlas retrieved
5389 skeletal muscle coding genes, and GTEx contained
7077 skeletal muscle-specific genes. To reduce the complex-
ity of analysis, we combined the transcriptome data
from Protein Atlas and GTEx to 10 962 genes. Our compiled
skeletal muscle shows 5024 genes for 5431 proteins. The
comparison of these datasets shows that there is likely
more of the proteome to be mapped in human skeletal
muscle (Figure 3).
Functional annotation of skeletal muscle proteome
To describe the skeletal muscle proteome, we characterized
the 5431 compiled proteins based on gene ontology (GO),
Uniprot keywords, and manual annotation. In particular, we
annotated proteins by Uniprot keywords when they were
available. When the Uniprot keyword was not available, we
used the GO annotations and then manually searched the
literature for an exact annotation. In all proteins with multi-
ple annotations, the literature was consulted, and the protein
was manually annotated towards its localization and function
in skeletal muscle. Protein numbers were normalized to the
total number of ontology annotation terms identified for all
the proteins. The justification for this annotation process is
as follows: GO provides a set of hierarchical controlled
vocabularies split into three categories: cellular component,
Figure 3 Comparison of approaches to human skeletal muscle prote-
ome. The 5024 genes identiﬁed from 38 human skeletal muscle publica-
tions (complied skeletal muscle human) were compared with
Genotype-tissue Expression V6 and Protein Atlas skeletal muscle tran-
scriptomics data (10 962) and mouse skeletal muscle proteome data
(9887). Mouse skeletal muscle shared 6559 genes (skeletal muscle
mouse) and transcriptome skeletal muscle from Protein Atlas and
Genotype-tissue Expression shared 5258 genes (skeletal muscle
transcriptome human). Two thousand, two hundred and eighty-three
genes were common between all three skeletal muscle studies. Text
in italics are genes unique for each study. Eighty-eight per cent of the
compiled skeletal muscle proteins were present in the transcriptome
and mouse skeletal muscle datasets.
12 M. Gonzalez-Freire et al.
Journal of Cachexia, Sarcopenia and Muscle 2017; 8: 5–18
DOI: 10.1002/jcsm.12121
molecular function, and biological process. However, GO is
designed to be species neutral, an approach that tends to de-
scribe very broad functional domains.91,92 UniProt contains a
controlled vocabulary that is specific to species. Therefore, to
make the annotation more relevant to human biology, we
combined the GO annotations with UniProt keyword annota-
tion and direct literature search.
By this process, we were able to annotate 5031 proteins
over 7934 terms for the cellular component, 4316 over
5795 for molecular function and, finally, 4395 proteins over
6501 terms for biological function. One hundred and three
serum proteins were excluded from both molecular function
and biological process. Some proteins are multiple counted
because they are in several compartments, or have different
molecular functions, or are involved in multiple different
biological processes.
Classiﬁcation of the human skeletal muscle proteome
based on the cellular components
Gene Ontology Consortium (GOC) defines the cellular compo-
nent as ‘locations, at the levels of subcellular structures and
macromolecular complexes’. Based on this, we classified
5031 proteins. We found that the majority of the skeletal
muscle proteins are compartmentalized in these major
compartments: cytoplasm (~30%), cell membrane (~24%),
nucleus (~19%), and mitochondria (~11%) (Figure 4A).
Membrane proteins include nuclear membrane, cell mem-
brane, inner and outer mitochondrial membrane, matrix
membrane, and Golgi membrane. Only a small percentage
(7%) of the proteins were not assigned to any compartment
(no information available), and we called them as ‘undeter-
mined’. Of note, a high percentage of proteins can be located
in multiple compartments (95%) (data not shown).
Figure 4 Classiﬁcation of the human skeletal muscle proteome. Based on gene ontology, Uniprot keywords and manual curation skeletal muscle
proteome were classiﬁed. (A) Classiﬁcation of the skeletal muscle proteome based on cellular components, (B) classiﬁcation of the skeletal muscle
proteome based on molecular function, and (C) classiﬁcation of the skeletal muscle proteome based on the biological process.
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Classiﬁcation of the human skeletal muscle proteome
based on the molecular function
GOC defines molecular function as ‘Elemental activities, such
as catalysis or binding, describing the actions of a gene
product at the molecular level’. Based on this definition, we
were able to define the molecular function of 4316 proteins
over 5795 annotated terms. Specifically, we identified 18
different major molecular functions (Figure 4B). In brief,
40% of the proteins have an enzymatic function and almost
56% (~1300 proteins) do not have any molecular functional
details. Interestingly, about one-half of the proteins identified
in the muscle have regulatory, structural and signalling func-
tion underlying the complexity of the muscle as a metabolic
and secretory organ, which is not limited to energetic metab-
olism. In fact, the TCA cycle, electron transport respiratory
chain, and ATP synthesis only constitute the 3.1% of the
skeletal muscle proteome (Figure 5A).
The highest percentage of molecular function annotations
is for enzymes (Figure 5B). Changes in the muscle enzyme
levels might be a signal of muscle damage or may underlie
some myopathies or another defective process during ageing
process, but there is no enough information in the literature
on this topic.
Classiﬁcation of the human skeletal muscle proteome
based on biological processes
Finally, we classified the skeletal muscle proteome based on
biological processes. GOC defines the biological process as
‘a recognized series of events or molecular functions with a
defined beginning and end’. Because we aimed for a parsimo-
nious approach, and because we found around 80 different
biological processes described, we summarized them into
15 major biological processes, namely, (i) ‘transport process’
that includes protein transport, lipid transport, ion transport,
electron transport, endocytosis, and exocytosis; (ii) ‘cell
cycle/process’ that includes cell shape, cell adhesion, cell
growth, chemotaxis, chemoattraction, cell proliferation,
apoptosis, angiogenesis, cell killing, autophagy, cell division,
mitosis, and meiosis; (iii) ‘metabolism’ that combines amino
acid, carbohydrate, ketone body, fatty acid, glycogen, glycan,
lipid, protein, nitrogen compound, and aldehyde metabolism;
(iv) ‘bioenergetics process’ that includes glycolysis, Krebs
cycle, pentose shunt, urea cycle, and ATP synthesis
(Figures 4C and 5A). Based on this, we were able to annotate
4395 proteins over 6501 annotated terms.
Future directions and gaps in
knowledge
By performing a comprehensive review of the literature, we
have shown that there are at least 5431 different proteins
in human skeletal muscle. In spite of the extensive work done
so far, our knowledge is still too limited to translate skeletal
muscle proteomics into a powerful clinical tool. First of all,
there are >200 muscles in the human body, and most of
the data available are based on biopsies collected almost
exclusively in the quadriceps and deltoid muscle. It is known
that there are considerable differences between muscles in
protein and enzymatic composition based on the muscle fibre
type composition; therefore, some of them will be mainly
glycolytic and involved in fast contractions, and others will
be primarily aerobic, and with a higher oxidative capacity.
Thus, the list of proteins reported here does not apply to
other specialized muscle types, such as laryngeal muscles
and extra-ocular muscles in humans. Also, skeletal muscle is
highly abundant in different proteoforms that may play an
important role in muscle function and could affect the com-
position of the skeletal muscle proteome. In addition, norma-
tive proteomic data on muscle proteomics in disease-free
men and women dispersed over a wide age range and
assessed by rigorous proteomic, and MS approaches and
state of the art technology are not available. The absence
Figure 5 (A) Bioenergetics process from skeletal muscle proteome. The major energy production chains and the number of proteins compiled for each
process as shown next to process. (B) Molecular function of enzymes. Enzymes predominate skeletal muscle protein molecular function. Text shows
molecular function of enzymes and number of proteins compiled next.
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of a solid reference atlas of skeletal muscle proteins makes
the identification of changes in the abundances of proteins
specifically associated with different disease or conditions a
formidable task.
Most of these obstacles are not insurmountable. For
example, vastus lateralis biopsies are being performed in
the Baltimore Longitudinal Study of Aging, the America’s
longest-running scientific study of human ageing, in partici-
pants dispersed over a wide age range who are selected to
be healthy according to very strict inclusion and exclusion
criteria that will increase the likelihood of producing reliable
and reproducible proteomic results among others.
Significant technological progress that was made in MS
over the last decade substantially improved quality of proteo-
mics data in fundamental biological and pathophysiological
research. Proteomic studies became a valuable asset for the
global tissue or cell-specific protein profiling, biomarker
discovery, and quantitative proteome studies. Enhanced mass
accuracy, acquisition rate, and sensitivity on some of the
newly released instruments in combination with advanced
liquid chromatography methods allow to record large
amounts of information and accurately identify peptides at a
very high confidence level. Thousands of proteins can be
identified just in a single shotgun experiment in a robust and
highly reproducible manner using simplified, accurately
controlled sample preparation protocols. Extremely complex
biological samples with challenging dynamic ranges, such as
skeletal muscle tissues or human plasma, can be analysed in
depth by employing advanced offline high performance liquid
chromatography/ultra light pressure liquid chromatography
(HPLC/UPLC) protein or peptide fractionation methods includ-
ing ion exchange, basic reverse phase, hydrophilic interaction
(HILIC), in solution isoelectric focusing (IEF), or traditional 1D,
2D gel electrophoresis techniques with dramatically increased
yield in protein discovery allowing detection of functionally
important low-abundant proteins (the ‘deep proteome’ analy-
sis).93–96 Furthermore, improved sample preparation and frac-
tionation techniques including isolated organelles such as
mitochondrial, nuclear, or membrane fractions as well as IP
of Tyr-phos proteins, pull down of, for example, 14-3-3 pro-
teins, pull down of interaction partners of specific signalling en-
zymes, for example, IRS-1, and so on can be also used to target
highly specialized organelle proteomes and unique protein
complexes in various cell models at different biological states.
Quantitative proteomic methods are also evolving rapidly
alongside with the improving instrument quality merging both
discovery and quantitative proteomic studies in one unified
analysis. Recently proposed SWATHTM technology,97 a unique
open window acquisition technique available on some of
triple TOFs or DIA protocols specific to some of the Orbitraps
are used today as a powerful alternative to some of the
traditional peptide-labelling techniques such as isobaric tag
labelling (iTRAQ or TMT).98,99 Peptide or protein-labelling
techniques are used broadly in proteomic studies for the
relative and absolute protein quantification in the complex
cell or tissue lysate analysis. Targeted methods in proteomics
such as selected/multiple reaction monitoring are widely used
as accurate quantitative assays but also as additional valida-
tion techniques in the discovery studies,100,101
Methods and instruments are also improving for the
detection of PTMs such as phosphorylation, glycosylation,
acetylation, ubiquitination, sumoylation, and so on. The
observation that acetylation and phosphorylation are often
identified on the same peptides and proteins, and probably
interact, is a new interesting area of research. PTMs are
important to study because they reflect the diversity of
protein function.73,102 Many of the PTMs are difficult to study
because they are labile to sample processing and LC-MS
artefacts. For example, O-GlcNAcylation, an important PTM
that rivals phosphorylation in abundance and distribution
and has been implicated in chronic diseases, has been espe-
cially challenging to detect and measure.103 At least in part,
advancements in this field are due to steep improvement of
bioinformatics tools and better search algorithms and pro-
teins reference databases. Many proteins have functions that
are unknown or not well understood. By studying the pro-
teins with which a particular protein interacts, it is possible
to deduce biological functions and pathways using in silico
structure-based approach.104 Protocols have recently been
developed for proteomic analysis of formalin-fixed and
paraffin-embedded tissues and equivalent to proteome
inventories obtained from frozen tissue specimens. Thus,
using also these tissues could be a valuable resource for
retrospective biomarker discovery studies.105
A single technique or method alone is not enough to
define or characterize a proteome. Because one of the most
challenging issues for the scientific community nowadays is
the identification of biological markers, all these advances
in the proteomic field together with high-throughput technol-
ogies such as genomics, metabolomics, and other ‘omics’ will
allow us to identify molecular pathways and novel protein–
protein interactions that are involved not only in pathological
conditions but also in normal human biology.
By establishing the Skeletal Muscle Proteome Project
Initiative, which recently (October 2015) was presented at
the Human Proteome Organization World Conference in
Vancouver, Canada, we will be able to characterize the prote-
ome of the normal human skeletal muscle during the entire
life cycle, including protein variants and PTMs. For this pur-
pose, we aim at promoting progress in this area by establish-
ing a collaborative network of scientists that can exchange
experiences, understand failure, start creating some initial
standard guidelines about the performance of muscle biop-
sies, sample preparation and fractionation, quality control,
statistical processing, and archival of muscle proteins so that
we can start pulling data created by different laboratory and
create the critical mass of information that is needed to
address the substantial challenges posed by this field.
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